Your session is about to expire
← Back to Search
BGB324 + Docetaxel for Non-Small Cell Lung Cancer
Study Summary
This trial is testing a new cancer drug to see if it's safe when combined with another existing cancer drug. They're also trying to find the highest dose that doesn't cause too many side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 32 Patients • NCT01301729Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has grown or returned after my last chemotherapy.My kidney function is good, with creatinine levels low or clearance high.You have a disease that can be measured or evaluated using a specific set of guidelines.I haven't had major surgery in the last 28 days, except for skin biopsies or procedures to insert a central venous access device.I am not on medication that affects heart rhythm and can't stop it before treatment.I have been treated with docetaxel or an Axl inhibitor before.I am not taking medication that is mainly broken down by CYP3A4 and has strict dosage limits.I cannot take medicine by mouth.I've had up to 3 cancer treatments, including one platinum-based.My lung cancer is confirmed to be at stage 4.My heart condition gets worse with mild activity.I have a slow heartbeat or have had heart rhythm problems needing treatment.I have a digestive condition like celiac or Crohn's that affects how my body absorbs medication.It has been weeks since my last cancer treatment or major surgery.I am not pregnant, can use birth control during the study, and if female, am not of childbearing potential or will use contraception.I do not have an active, uncontrolled brain condition.I had treatment for brain cancer spread and don't need steroids.My side effects from previous treatments are mild or gone, except for hair loss.My liver tests are within normal ranges, or slightly elevated if I have liver cancer.I do not have an active HIV, hepatitis B, or C infection.I have enough tissue samples for testing.I have a family or personal history of abnormal heart rhythms.I am currently on medication for an infection.My lung cancer shows a hollow spot in the center on scans.I do not have severe health issues that could affect my study participation.Your blood takes longer than usual to clot.I had a severe reaction to a medication that affected my heart's rhythm, leading to stopping the treatment.I have moderate to severe numbness, tingling, or pain in my hands or feet.I haven't coughed up more than a teaspoon of blood in the last 6 weeks.My heart condition has been stable, without medication changes, for the last 3 months.My heart's pumping ability is below normal.I am 18 years old or older.My cancer has worsened after targeted therapy and chemotherapy.Your ECG shows a particular measurement called "QTc" that is too long.I am fully active or can carry out light work.I have had a heart attack or similar heart issue in the last 3 months.I have had surgery on my intestines that might affect how drugs are absorbed.My blood counts meet the required levels for treatment.
- Group 1: BGB324 in combination with docetaxel
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the scope of participation for this research project?
"This trial is no longer recruiting new patients, as the last update took place on June 28th 2022. If you're interested in other research studies related to non-small cell lung carcinoma (nsclc), there are currently 1,527 trials open for enrollment and 323 clinical trials focused on BGB324 that need participants."
Has the regulatory body approved of BGB324 for public consumption?
"The safety of BGB324 is estimated to be a 1 on the scale due its status as an early-phase trial with limited evidence for both efficacy and security."
Is enrollment currently possible for this investigation?
"According to clinicaltrials.gov, this trial has ceased participant recruitment and is no longer enrolling patients. Initially posted on November 1st 2016, the study was last updated on June 28th 2022; however, there are over 1800 other medical trials actively recruiting at present."
Has BGB324 been tested in any other scientific research projects?
"Presently, there are 323 trials in progress for BGB324 with 126 of those experiments being located at Phase 3. While the majority take place around Fuzhou, Fujian, a total of 22403 sites are running studies for this drug regimen."
What therapeutic benefits has BGB324 been known to provide?
"BGB324 is the go-to medication for treating malignant neoplasms and has been observed to provide benefit in other conditions, such as advance directives, sarcoma, and esophageal neoplasms."
Share this study with friends
Copy Link
Messenger